ARTICLE | Clinical News

Alpharadin radium-223: Additional Phase II data

June 13, 2011 7:00 AM UTC

Additional data from the double-blind Phase II BC1-04 trial in 75 evaluable patients showed that 25, 50 and 80 kBq/kg IV Alpharadin led to normalization of b-ALP in 17%, 40% and 48% of patients, respectively. Median survival for patients with and without b-ALP normalization was 102 and 58 weeks, respectively. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...